Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Former FDA supplement programs head Bill Frankos says the industry bears the burden for monitoring product safety in the marketplace because FDA does not have the same vested interest it has for drugs and medical devices stemming from pre-market approval of the products.

You may also be interested in...



FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues

AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements

FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations

Supplement GMPs Stress Responsibility, Put Firms In Driver’s Seat For Testing

The dietary supplement good manufacturing practices final rule provides "a very flexible framework for required testing," said Vasilios H. Frankos, director of the dietary supplement programs division for FDA's Center for Food Safety and Applied Nutrition

Topics

Related Companies

UsernamePublicRestriction

Register

PS078671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel